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Abstract--Extracts of human neutrophils were examined for phosphodiesterase 
activity using a radiochemical assay. As reported by other investigators, both high- 
and low-K m forms of the enzyme were found. Although calmodulin could be 
measured in these extracts, human neutrophil phosphodiesterase proved not to be 
calmodulin dependent. Activity of the neutrophil phosphodiesterase was also not 
altered by physiologic concentrations of indomethacin, p-bromophenacyl bro- 
mide, eicosatetraenoic acid, or eicosatetraynoic acid, alI inhibitors of arachidnnic 
acid metabolism. These results are relevant to stimulus secretion coupling in 
neutrophits, wherein calmodulin-dependent reactions piay a vital role. 
INTRODUCTION 
One of the earliest events in neutrophil activation is a transient increment in 
cAMP levels (1, 2). While the precise role of cyclic nucleotides in stimu- 
lus-response coupling remains to be elucidated (! 3), the promptness of the 
cAMP response and its potential as a second messenger have made it the 
subject of intensive investigation. On the other hand, the enzymes regulating 
cyclic nucleotide levels in these cells, namely adenylate (or guanylate) eyclase 
and phosphodiesterase, have received scant attention. The most recent work 
in this field is by Smith and Peters (4), who reported that human neutrophil 
phosphodiesterase is cytosolic and has both high- and low-K m forms. 
While the role of cyclic nucleotides in stimulus-secretion coupting in 
neutrophils is unclear, that of intraceltular calcium is not. The mobilization of 
membrane-bound calcium (5-8), with attendant rises in intracellular free 
calcium (9, 10) and activation of calmodulin-dependent reactions (8, l l )  
constitutes a widely held concept of stimulus-response coupling for these 
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cells, I n d e e d ,  n e u t r o p h i l  r e s p o n s i v e n e s s  can  be c o m p l e t e l y  b l o c k e d  by  
a n t a g o n i s t s  o f i n t r a c e l l u l a r  c a l c i u m  and  c a l m o d u l i n  (8, 11). S ince  m a n y  f o r m s  
of  p h o s p h o d i e s t e r a s e  in o t h e r  t issues  are  c a l m o d u l i n  a c t i v a t a b l e  (12-14) ,  it 
was  o f  in t e res t  to  see if  c a l c i u m  m o b i l i z a t i o n  and c a l m o d u l i n  cou ld  affect  
p h o s p h o d i e s t e r a s e  in these  ceils, t h e r e b y  p o t e n t i a l l y  m o d u l a t i n g  cycl ic  
n u c l e o t i d e  m e t a b o l i s m .  In  essence ,  we f o u n d  tha t  h u m a n  n e u t r o p h i l  p h o s p h o -  
d ies te rase  was n o t  a f fec ted  by c a l m o d u l i n  o r  its an t agon i s t s ,  sugges t ing  tha t  
r e g u l a t i o n  o f  e n z y m a t i c  ac t iv i ty  was a c c o m p l i s h e d  by s o m e  o t h e r  m e c h -  
anism(s) ,  
M A T E R I A L S  A N D  M E T H O D S  
Reagents. Calmodulin (phosphodiesterase activator), activator-deficient phosphodies- 
terase, 5'-nucleotidase, p-bromophenacyl bromide, cAMP, 5'-AMP, and adenosine were 
purchased from Sigma Chemical Company, St. Louis, Missouri. TMB-8 was a gift from Robert 
J. Smith (Upjohn Company), and W-7 was a generous gift of Hiroyoshi Hidaka (Mie University 
School of Medicine). ETYA and ET1 were generously provided by Aaron Marcus, 
Preparation of Cell Suspensions. Purified preparations of neutrophils were isolated from 
heparinized ( 10 units/ml) venous blood by means of Hypaque-Ficoll gradients (15), followed by 
standard techniques of dextran sedimentation and hypotonic lysis of erythrocytes (16). 
Phosphodiesterase Assay. Pellets of human neutrophils were resuspended in an equal 
volume of "assay buffer," consisting of 40 mM Tris HC1, pH K0, 5 mM MgCt2, and 1 mM 
dithiothreitol. This suspension was sonicated and then centrifuged for 15 min at 15,000g. The 
resulting supernatant0 hereafter referred to as "extract," was harvested and employed as a source 
of endogenous neutrophil phosphodiesterase. The assay procedure was a minor modification of 
that published by Thompson et al. ( 17). In essence, 20 ~1 of extract was incubated for ! h at 37 ~ in 
300 tA of assay buffer containing 300 #M CaCI2 and 1 mM [3H]cAMP (0.5 ~zCi/mt; New England 
Nuclear). The incubation was stopped by placing the tubes in a boiling-water bath for 3 mix. 
After cooling, 50 mU of 5'-nucleotidase was added and incubation proceded for 10 rain more at 
37 ~ ;-this step converted 5'-AMP, produced from cAMP by phosphodiesterase, to adenosine. 
U nreacted cAMP was then removed by addition of 1 mt of a 2 : 1 slurry of anion exchange resin 
(Biorad AGt-X2). After equilibration for 15 rain at room temperature, the resin was centrifuged 
down and aliquots of the supernatant were taken for determination of [3H]adenosine by 
scintillation eounting. For each experiment, controls were run to determine the extent of 
trapping of [3H]cAMP and [3H]adenosine by the anion-exchange resin and appropriate 
corrections were applied to the calculations. 
Determination of Calmodulin Activity. Calmodulin present in the neutrophil extracts was 
most accurately determined by means of radioimmunoassay (CAABCO, Houston, Texas). Its 
biologic activity was assayed as follows. Extracts were boiled for 3 min to inactivate endogenous 
phosphodiesterase and other enzymes. Floeculent material was removed by centrifugation. 
Calmodulin activity was assayed in the system described above, using 1 mU of commercially 
available activator-dependent phosphodiesterase. Calmodulin present in the boiled extract thus 
increased the measured activity of the exogenous phosphodiesterase. Routine controls, applied 
during each experiment, included removal of calcium by EGTA and addition of the calmodulin 
antagonist trifluoperazine. 
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Fig. 1.-The phosphodiesterase activity in various volumes of neutrophil extract was measured. 
The assays were performed in the presence of 0.3 mM CaCI2 (Ca2+), 0.4 raM EGTA, 30 #M 
trifluoperazine, or in the absence of these agents (control). 
RESULTS 
Soluble extracts of human neutrophils contained phosphodiesterase 
activity which was readily measured by the two-step assay system described in 
Materials and Methods. Analysis of the kinetics of enzymatic activity 
revealed two forms of the enzyme, having values for apparent K m of 920 • 
440 t~M (N=  8) and 20 • 9 #M (N= 10); these values agree closely with those 
reported by Smith and Peters (4). Figure 1 shows that high-Kin ph0sphodies- 
terase activity was linear wiih respect to extract volume assayed, as expected. 
However, activity of the enzyme from neutrophils was not altered by the 
presence or absence of calcium or the presence of the calmodulin inhibitor 
trifluoperazine. Thus, it appeared the neutrophil phosphodiesterase was 
insensitive to calrnodulin. 
Figures 2 and 3 show attempts to activate neutrophil phosphodiesterase 
by the direct addition of commercially available calmodulin in the presence of 
calcium. As can be seen, calmodulin had no significant effect upon the kinetic 
parameters of either the high-Kin (Figure 2) or low-K,~ (Figure 3) form of the 
enzyme. Furthermore, high-K,~ neutrophil phosphodiesterase was not 
affected by the calmodulin inhibitor W-7, the intracellular calcium antagonist 
TMB-8, or EGTA (Figure 4). These results were not due to any inherent 
deficiencies in the assay system since activation of exogenous phosphodies- 
terase by either commercial or neutrophil calmodulin was blocked by EGTA, 
W-7, or trifluoperazine (not shown). These results were also not due to a lack 
of ealmodulin in the neutrophil extracts; calmodulin was detected by 
radioimmunoassay at a concentration of 9 pmol/106 cells, a value in accord 
with that reported by Chafouleas et al (18). Biologic activity of endogenous 
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Fig. 2, Extracts from human neutrophils were assayed for phosphodiesterase activity in the 
presence of various concentrations of substrate. For the indicated data points, calmodulin (200 
mU) was also present, The results are from a single representative experiment and provide values 
from apparent K~ of 593/aM (control) and 585 taM (calmodu[Jn). 
calmodulin was also demonstrated by its ability to activate susceptible 
commercial phosphodiesterase. 
Figure 5 shows the effect of several inhibitors of arachidonic acid 
metabolism on neutrophil phosphodiesterase. At physiologic concentrations 
(10-50 #M), indomethacin (a eyclooxygenase inhibitor), BPB (a phospholi- 
pase A2 inhibitor), and ETYA and ETI (bOth combined inhibitors of 
lipoxygenase and eyelooxygenase) all had little or no effect uPon the enzyme. 
However, at higher concentrations, indomethacin, ETYA, and ETI all 
Significantly inhibited phosphodiestcrase activity. 
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Fig. 3. Extracts from human neutrophils were assayed for phosphodiesterase actwity in the 
presence of various concentrations of substrate. For the indicated data points, calmodulin (200 
mU) was also present. The results are from a single representative experiment and provide va~,ues 
for apparent Km of 22 #M (control) and 18 taM (calmodulin). 
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Fig. 4. Extracts from human neutrophils were assayed for high=K~ phosphodiesterase activity 
in the presence Of the indicated concentrations of inhibitors. The results represent the means 
(• SD," N = 4 6) of the percentages of control phosphodiesterase samples, to which no inhibitors 
were added. 
DISCUSSION 
In spite of the potential importance of cyclic nucteotides in modulating 
stimulus-secretion coupling in neutrophils, the enzymes involved in cyclic 
nucleotide metabolism have not been the subject of intensive investigation. 
With respect to human neutrophil phosphodiesterase, Smith and Peters (4) 
reported that it had a cytosolic localization and was found in high- and low- 
Km forms. Our use of supernatant extracts from neutrophils as a source of 
phosphodiesterase activity is consistent with a cytoplasmic localization for 
this enzyme. Furthermore, our values for K m agree with those published by 









-~i E] BPB 
o ETI 
- - -  =----~" . . . .  ~ -  ~ ETYA 
- - ~  [ndomethocin 
1 j 
I 0 0  I,OOO 
Inhibitor Concentration (juM) 
Fig. 5. Extracts from human neutrophils were assaYed for high-K,, phosphodiesterase activity in 
the presence of the indicated concentrations ofinhibitors, The results represent the means ( !  SD; 
N = 4 6) of the percentages of control phosphodiesterase samples, to which no inhihitnrs were 
added. 
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Of considerable interest was our observation that neutrophil phospho- 
diesterase was not affected by calmodulin, calmodulin antagonists, calcium, 
or calcium antagonists. Thus, unlike phosphodiesterases from a variety of 
other cell types (12-14), this enzyme does not appear to regulated by calcium 
or ealmodulin. While insensitivity to ealmodulin is not unknown for other 
phosphodiesterases (12), it is, apparently, relatively rare. Since it is known 
that stimulation of neutrophils involves increases in cytosolic free calcium 
(either as a result of intracellular calcium mobilization or of influxes from the 
medium) as well as obligatory calmodulin-dependent reactions (5-1 l), this 
finding is significant. One ramification of this is that the recovery of baseline 
levels of cAMP following stimulation (1-3) is not due to calmodulin 
activation of phosphodiesterase. These studies thus emphasize the need for 
examining calmodulin requirements, if any, of neutrophil adenylate cyclase. 
In view of their wide use in neutrophil research, inhibitors of lipid 
metabolism were employed to look for nonspecific inhibition of a neutrophil 
enzyme. As expected, indomethacin, BPB, ETYA, and ETI were without 
effect at normal physiologic concentrations (10-30 ~M). However, at higher 
concentrations, inhibition of phosphodiesterase activity occurred, a result 
which is most likely nonspecific. Thus, these results emphasize the impor- 
tance of using physiologic concentrations of these inhibitors and provide an 
example of an enzymic activity which can be nonspecifically inhibited. 
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